news aktuell GmbH

Maren Thurow starts as new Head Global Communications at Grünenthal

20.5.2025 10:52:20 CEST | news aktuell GmbH | Press Release

Share
Maren Thurow took over the role of Vice President and Head Global Communications at Grünenthal.
Maren Thurow took over the role of Vice President and Head Global Communications at Grünenthal.

Aachen, Germany, 20th May 2025 - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at the company’s headquarters in Aachen. She will report directly to CEO Gabriel Baertschi.

This appointment comes at a pivotal moment in Grünenthal’s transformation, following the company’s outstanding financial performance in 2024. Since 2017, Grünenthal’s profitability, measured by adjusted EBITDA, has more than tripled, driven by strategic acquisitions and partnerships such as the acquisition of the US company Valinor Pharma and the product Movantik™ in July 2024. Additionally, Grünenthal continues to advance its key R&D programs, including progressing the Glucocorticoid Receptor Modulator (GRM) and Nociceptin (NOP) Receptor Agonist programs to the next development stages, along with ongoing progress in its Nav compounds. The company is also focusing on accelerating growth in Qutenza™ and its Established Brands, while ensuring a smooth integration of Valinor Pharma and pursuing further strategic acquisitions.

Maren joined Grünenthal in 2021 as Head of Global Commercial Communication and was subsequently the Planning Director for the company’s commercial organization. Prior to joining Grünenthal Maren was a Director at FleishmanHillard, one of the world’s leading global PR firms.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion.

More information: https://www.grunenthal.com

Follow us on: LinkedIn: Grunenthal Group

Instagram: grunenthal

 

Click here for our Grünenthal Report 2024/2025

Contacts

Maren Thurow, Head Global Communications at Grünenthal
maren.thurow@grunenthal.com

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:28:38 CEST | Press Release

New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found. The report, “The Governance Performance of the Fifty States: The U.S. Berggruen Governance Index”, applies the research team’s “governance triangle” from past global country rankings to the 50 US states. The report has now been presented to the public at Columbia University in New York. “Unlike in the Berggruen Governance Index’s cross-national comparisons, where the three dimensions are broadly correlated, in the 50 U.S. states they often run counter to each other,” the authors conclude. “This may seem counterintuitive, as one might expect a well-governed state to finish high on all three and a poor

Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 09:23:41 CEST | Press Release

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye